Guardant Health (GH) revenue breakdown
By product, Oncology is the largest at 70% of fiscal 2025 revenue; Screening grew fastest, 1456% a year over 1 years.
By region, United States is the largest at 94% of fiscal 2025 revenue, growing 42% a year over 7 years.
Revenue by product
Fiscal years, as Guardant Health reports them in its 10-K filings; fiscal 2025 total $982M.
| Products | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| Oncology | $404M | $543M | $684M | 70% |
| Biopharma and data | $136M | $178M | $210M | 21% |
| Screening | — | $5M | $80M | 8% |
| Licensing and other | $24M | $13M | $9M | 1% |
Revenue by region
Fiscal years, as Guardant Health reports them in its 10-K filings; fiscal 2025 total $982M.
| Regions | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| United States | $78M | $194M | $265M | $353M | $421M | $527M | $697M | $923M | 94% |
| International | $13M | $20M | $22M | $21M | $29M | $37M | $42M | $59M | 6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for GH.
Open GH in InvestinglyQuestions
Where does Guardant Health make its money?
In fiscal 2025, by product: Oncology $684M, Biopharma and data $210M, Screening $80M, Licensing and other $9M.
From Guardant Health's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.